Overview

A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors

Status:
Recruiting
Trial end date:
2025-08-15
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ES009 administered intravenously to subjects with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Elpiscience Biopharma Australia Pty. Ltd.